CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Non-alcoholic fatty liver disease

Comorbid ConditionsDisease / conditionriskpartially modifiable
53
evidence score

Also known as: NAFLD/MASLD, Non-alcoholic fatty liver disease (NAFLD), Nonalcoholic fatty liver disease (NAFLD), fatty liver, hepatic steatosis, masld, nafld, non-alcoholic fatty liver, non-alcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver, nonalcoholic fatty liver disease

PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 20.7meta-analyses: 17.6trials: 15genetic: 0MR bonus:

References (117)

6 meta-analyses / systematic reviews

Clinical trials (40)

NCTTitleStatusTypeInterventions
NCT07246421Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 DiabetesRECRUITINGINTERVENTIONALGlugagon
NCT07238985Evaluating the Safety and Efficacy of Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease Patients.RECRUITINGINTERVENTIONALStandard therapy, Cilostazol
NCT07130318Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Elliptical Aerobic ExerciseRECRUITINGINTERVENTIONALexercise plus diet restriction, diet restriction
NCT06751862The Effect of Simple Carbohydrates on the Development of Non-alcoholic Fatty Liver Disease (FROGLOSA)RECRUITINGINTERVENTIONAL150g of fat with glucose, 150g of fat with fructose, 150g of fat with sucrose
NCT07272343A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular MechanismsRECRUITINGINTERVENTIONALsemaglutide, caloric restriction
NCT03875625Change of Adipose Tissues and Triglyceride in Obese Patients With Non-alcoholic Fatty Liver Disease After Bariatric Surgery or Life-style InterventionRECRUITINGINTERVENTIONALBariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
NCT03867487SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseaseNOT YET RECRUITINGINTERVENTIONALEmpagliflozin 10 MG, Placebo Oral Tablet
NCT07391267Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide - a Randomized Controlled Trial.NOT YET RECRUITINGINTERVENTIONALSemaglutide Oral Tablet, Placebo, Standard medical treatment
NCT06117137The Impact Of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes MellitusCOMPLETEDINTERVENTIONALSGLT2 inhibitor
NCT06005012Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMUNKNOWNINTERVENTIONALSemaglutide, Placebo
NCT05720702A Feasibility Trial of One-carbon Metabolism Cofactor Supplements for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)COMPLETEDINTERVENTIONALhomocysteine (Hcy) lowering supplements
NCT07338331Comparison Between the Effect of Aspirin and SGLT2 Inhibitor Intake in Non-Alcoholic Fatty Liver on Liver Enzymes, Lipid Profile, and the Results of FibroScanCOMPLETEDINTERVENTIONALAspirin, Dapagliflozin (10Mg Tab) along with standard medical therapy
NCT03970031MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1UNKNOWNINTERVENTIONALMSDC-0602K, Placebo
NCT07539584Adiponectin and Its Role in the Treatment of Patients With Metabolic DisordersCOMPLETEDINTERVENTIONALSGLT2 inhibitor, GLP-1 RA
NCT04976283Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control TrialUNKNOWNINTERVENTIONALPioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
NCT05259475Ectopic Fat in Singaporean Women - the Culprit Leading to Gestational Diabetes, Metabolic Syndrome, and Type 2 DiabetesCOMPLETEDINTERVENTIONALLifestyle Advice, Diet Intervention, OCFA Meal-Based Diet-Intervention
NCT04642261Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled TrialCOMPLETEDINTERVENTIONALEmpagliflozin 10 MG, Placebo pills
NCT05764811Mechanism of the Effect by Sodium-glucose Cotransporter-2 Inhibitor on Obesity Associated CardiomyopathyCOMPLETEDINTERVENTIONALCanagliflozin 100mg
NCT04042142In-depth Studies of Glucagon Resistance on Hepatic Glucose, Fatty Acid and Triglyceride Kinetics and Generation of Toxic Lipid Intermediates in NAFLD and NASH.COMPLETEDINTERVENTIONALglucagon
NCT02681055An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With HypertriglyceridemiaCOMPLETEDINTERVENTIONALMN-001
NCT02696941SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitisCOMPLETEDINTERVENTIONALMetformin, SGLT2 inhibitor
NCT02649465Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty LiverCOMPLETEDINTERVENTIONALTofogliflozin, Glimepiride
NCT02660047Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian DescentCOMPLETEDINTERVENTIONALLiraglutide, Liraglutide - Placebo
NCT02820285Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASHCOMPLETEDINTERVENTIONALEvaluation of the staging of fibrosis liver, Determine the expression level of semaphorin, Determination of the composition of immunity cells
NCT02644239Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory EpilepsyUNKNOWNINTERVENTIONALketogenic diet
NCT01355575RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?TERMINATEDINTERVENTIONALRifaximin
NCT01094158A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASHCOMPLETEDINTERVENTIONALAramchol, Aramchol, Placebo
NCT01790984How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype?COMPLETEDINTERVENTIONALHigh sugar low starch diet, Low sugar high starch diet
NCT01834300The Effects of Exercise Training on Visceral Fat, Insulin Sensitivity, Β-cell Function and Triglyceride Kinetics in Patients with Non-alcoholic Fatty Liver Disease (NAFLD).COMPLETEDINTERVENTIONALUnsupervised exercise training, Supervised exercise training
NCT00546455Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty LiverSUSPENDEDINTERVENTIONALFenretinide, Placebo
NCT00160407Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)COMPLETEDINTERVENTIONALOrlistat (Xenical), 1400 kcal diet (30% fat)
NCT07567378Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition SubcohortNOT YET RECRUITINGOBSERVATIONALTirzepatide
NCT07269197The Association of Sodium-Glucose Cotransporter 2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Patients With Type 2 Diabetes MellitusCOMPLETEDOBSERVATIONALSodium Glucose Co-transporter 2 (SGLT2) Inhibitor
NCT05637866Effect of Soy Milk for Cow's Milk on Intermediate Cardiometabolic Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsUNKNOWNOBSERVATIONALSoy milk
NCT05486429Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by UltrasoundUNKNOWNOBSERVATIONALAbdominal ultrasound and lipid profile
NCT06933745Ultrasound of Carotid and Femoral Plaque Burden and Non-alcoholic Fatty Liver Disease as Predictors of Cardiovascular DiseaseCOMPLETEDOBSERVATIONAL
NCT04820556The Development of Preventive Methods for Chronic Noncommunicable Diseases Based on Modulation of Gut Microbiota Composition and FunctionCOMPLETEDOBSERVATIONAL
NCT04774302Study of Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With Nonalcoholic Fatty Liver DiseaseCOMPLETEDOBSERVATIONAL
NCT04524936Relation of Serum Irisin Levels, Non-Alcoholic Fatty Liver Disease, Glucose and Lipid Metabolism Parameters in Obese ChildrenCOMPLETEDOBSERVATIONALblood sample
NCT02716870Effect of Important Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial DesignUNKNOWNOBSERVATIONALFructose-containing Sugars

Genetic associations (0)

None linked.